Net sales were $5.49 billion for the third quarter of 2009, compared to $5.25 billion for the same quarter of 2008.
Net income attributable to the company for the nine months ended September 30, 2009 was $2.59 billion, or $1.30 per diluted share, compared to $4 billion, or $2 per diluted share, for the nine months ended September 30, 2008.
Net sales were $15.89 billion for the nine months ended September 30, 2009, compared to $15.35 billion for the prior-year period.
James Cornelius, chairman and CEO of Bristol-Myers, said: "The performance in the third quarter of 2009 clearly shows the results of our outstanding business performance, disciplined financial management and overall strategic execution.
"We are transforming Bristol-Myers Squibb into a biopharma leader and the recent approval and launch of Onglyza for the treatment of type 2 diabetes is a great example of what we do best: discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index